Classifications

• • G—PHYSICS
  • G02—OPTICS
  • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
  • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
  • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
  • G02B1/041—Lenses
  • G02B1/043—Contact lenses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents

Definitions

• the present invention generally relates to ophthalmic devices such as contact lenses having a high water content with improved evaporative dehydration.
• Soft contact lenses have been available since the 1980s. It is important that contact lenses be comfortable and safe to wear. However, while there are many people who can successfully wear contact lenses, there are a number of people who can wear contact lenses for only a short period of time due to, for example, contact lens related dry eye. Symptoms of this disorder include, for example, thin and/or unstable tear films, corneal staining and subjective symptoms such as ocular discomfort, burning/stinging and dryness. Contact lens wear may trigger the onset of these symptoms or may exacerbate the symptoms.
• lenses with high water contents are softer, more lubricious and more comfortable to wear, such lenses may not have one or more properties useful to provide comfortable and safe wearing of the contact lenses.
• a particular problem associated with high water content contact lenses is evaporative corneal dehydration. As free water in the lens is lost due to evaporation, it is replaced with water from the cornea. Evaporative water loss at the anterior lens surface is a potential cause of contact lens dehydration and of post-tens tear-film depletion, which in turn, may lead to discomfort, dry eye, corneal staining and/or other damage to the eye. Dehydration of the epithelium results in corneal damage and therefore corneal staining.
• This staining is usually limited to the superficial 2 to 3 layers of the epithelium and spread over the inferior portion of the cornea, but if the stimulus is sufficiently great, damage can be deep and severe allowing rapid diffusion of fluorescein into the stroma.
• the staining can occur rapidly within a few hours of lens insertion but can take 4 to 6 hours or more.
• high water content contact lenses were typically made by lathing the high water content lens from a cylindrical blank of polymerized lens material (cylindrical blanks are commonly referred to as a "button").
• the high water content contact lenses are made by (a) polymerizing the initial monomelic mixture in tubes to provide rod-shaped articles, (b) cutting the rods into buttons, and (c) lathing the buttons into contact lenses.
• a surface of a lens produced from lathed buttons can be quite different from the surface of a lens cast from molds.
• U.S. Patent No. 6,245,830 discloses a high water content and high water balance contact lens made of a homopolymer or copolymer having more than 80 mole percent and preferably more than 90 mol percent of 2,3-dihydroxypropyl methacrylate (GMA) and up to 20 mol percent, generally from 0.05 up to 10 mol percent of a reactive pyrrolidone such as N-vinyl pyrrolidone.
• GMA 2,3-dihydroxypropyl methacrylate
• U.S. Patent No. 6,627,674 discloses a high water content and high water balance contact lens made of a homopolymer or copolymer having more than 80 mole percent and preferably more than 90 mol percent of GMA and having an equilibrium water content of at least about 60 percent by weight and the contact lens has a water balance of more than about 8 relative to poly(2-hydroxyethyl methacrylate).
• the '674 patent further discloses that GMA polymers can be polymerized in the presence of a reactive polar aprotic diluent, such as N-vinyl pyrrolidone and/or a non-reactive polar aprotic diluent.
• an ophthalmic device is provided that is a polymerization product of a monomeric mixture comprising: (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the surface of the ophthalmic device substantially inhibits evaporative dehydration.
• an ophthalmic device is provided that is a polymerization product of a monomeric mixture comprising: (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device exhibits a dehydration rate of less than or equal to about 0.600 mg/minute.
• a method comprising the step of casting a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent in a hydrophobic substrate to form an ophthalmic device having an evaporative dehydration barrier layer on the surface thereof and wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent.
• a method for substantially mitigating evaporative corneal dehydration associated with an ophthalmic device having an equilibrium water content of at least about 70 weight percent comprising contacting an eye of a subject with an ophthalmic device that is a polymerization product of a monomeric mixture comprising: (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device has an evaporative dehydration barrier layer on the surface thereof.
• subject or "a patient” or “a host” as used herein refers to mammalian animals, preferably human.
• mitigating shall be understood to mean (1) preventing or delaying the appearance of one or more clinical symptoms of the evaporative corneal dehydration developing in a subject that may be afflicted with evaporative corneal dehydration but does not yet experience or display symptoms of evaporative corneal dehydration, (2) inhibiting evaporative corneal dehydration, i.e., arresting or reducing the development of evaporative corneal dehydration in a subject, or (3) relieving evaporative corneal dehydration, i.e., causing regression of evaporative corneal dehydration in a subject.
• the high water content ophthalmic devices of the present invention advantageously mitigate evaporative corneal dehydration in an eye of a subject by possessing an evaporative dehydration barrier layer on the surface of the device.
• the device can be worn in the eye for an extended period of time with long term corneal health to the cornea of the eye.
• the evaporative dehydration barrier layer is formed by polymerizing (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent against a hydrophobic substrate such that the hydrophobic monomer is driven to the surface of the device resulting in a evaporative dehydration barrier layer on the surface of the device.
• Figure 1 is a graph illustrating the rate of dehydration of the contact lens of Example 1 versus commercially available contact lenses.
• the present invention is directed to high water content ophthalmic devices. Although the invention is applicable to a variety of high water content ophthalmic devices, the invention is especially useful and advantageous for high water content contact lenses.
• the terms "opthalmic device” and “lens” refer to devices that reside in or on the eye. These devices can provide optical correction, wound care, drug delivery, diagnostic functionality or cosmetic enhancement or any combination of these properties. Representative examples of such devices include, but are not limited to, soft contact lenses, e.g., soft, hydrogel lenses, soft, non-hydrogel lenses and the like, hard contact lenses, e.g., hard, gas permeable lens materials and the like, intraocular lenses, overlay lenses, ocular inserts, optical inserts and the like.
• a lens is considered to be "soft” if it can be folded back upon itself without breaking.
• the high water content ophthalmic devices such as high water content contact lenses of the present invention can be spherical, toric, bifocal, may contain cosmetic tints, opaque cosmetic patterns, combinations thereof and the like.
• the high water content ophthalmic devices of the present invention will have an equilibrium water content of at least about 70 weight percent. In one embodiment, the high water content ophthalmic devices of the present invention will have an equilibrium water content of at least about 80 weight percent.
• the high water content ophthalmic devices are a polymerization product of a monomeric mixture including at least (a) a major amount of a non-silicone -containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent.
• Suitable non-silicone-containing hydrophilic monomers include amides such as N,N-dimethylacrylamide, N,N-dimethylmethacrylamide and the like, cyclic lactams such as N-vinyl-2-pyrrolidone and the like, poly(alkene glycols) functionalized with polymerizable groups and the like.
• useful functionalized poly(alkene glycols) include poly(diethylene glycols) of varying chain length containing monomethacrylate or dimethacrylate end caps.
• the poly(alkene glycol) polymer contains at least two alkene glycol monomeric units.
• Still further examples are the hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S.
• Patent No. 5,070,215 and the hydrophilic oxazolone monomers disclosed in U.S. Patent No. 4,910,277.
• Other suitable hydrophilic monomers will be apparent to one skilled in the art. Mixtures of the foregoing non-silicone-containing hydrophilic monomers can also be used in the monomeric mixtures herein.
• hydrophilic monomers such as a N-vinyl lactam-containing monomer are present in the monomeric mixture in a major amount, e.g., an amount greater than or equal to about 70 weight percent and preferably greater than or equal to about 80 weight percent, based on the total weight of the monomeric mixture.
• Suitable hydrophobic monomers (b) include ethylenically unsaturated hydrophobic monomers such as, for example, (meth)acrylates-containing hydrophobic monomers, N-alkyl (meth)acrylamides-containing hydrophobic monomers, alkyl vinylcarbonates-containing hydrophobic monomers, alkyl vinylcarbamates-containing hydrophobic monomers, fluoroalkyl (meth)acrylates-containing hydrophobic monomers, N-fluoroalkyl (meth)acrylamides-containing hydrophobic monomers, N-fluoroalkyl vinylcarbonates-containing hydrophobic monomers, N-fluoroalkyl vinylcarbamates- containing hydrophobic monomers, silicone -containing (meth)acrylates-containing hydrophobic monomers, (meth)acrylamides-containing hydrophobic monomers, vinyl carbonates-containing hydrophobic monomers, vinyl carbamates-containing hydrophobic monomers, styrenic -containing hydrophobic monomers, polyoxypropylene
• (meth) denotes an optional methyl substituent.
• terms such as “(meth)acrylate” denotes either methacrylate or acrylate
• (meth)acrylamide denotes either methacrylamide or acrylamide.
• a hydrophobic monomer is represented by Formula I:
• R 1 is methyl or hydrogen
• R 2 is -O- or -NH-
• R 3 and R 4 are independently a divalent radical selected from the group consisting of -CH 2 -, -CHOH- and -CHR 6 -
• R 5 and R 6 are independently a branched C 3 -Cs alkyl group
• n is an integer of at least 1
• m and p are independently O or an integer of at least 1 , provided that the sum of m, p and n is 2, 3, 4 or 5.
• hydrophobic monomers (b) include, but are not limited to, 4-t-butyl-2-hydroxycyclohexyl methacrylate (TBE); 4-t-butyl-2- hydroxycyclopentyl methacrylate; 4-t-butyl-2-hydroxycyclohexyl methacrylamide (TBA); ⁇ -isopentyl-S-hydroxycyclohexyl methacrylate; and 2-isohexyl-5- hydroxycyclopentyl methacrylamide.
• Preferred hydrophobic monomers (b) include compounds of formula I wherein R 3 is -CH 2 -, m is 1 or 2, p is 0, and the sum of m and n is 3 or 4. TBE and TBA are especially preferred.
• the hydrophobic monomer will ordinarily be present in the monomeric mixture in an amount ranging from about 0.5 to about 25 and preferably from about 1 to about 10 weight percent, based on the total weight of the monomeric mixture.
• crosslinking agents for use herein are known in the art.
• a useful crosslinking monomer can have at least two polymerizable functional groups.
• Representative crosslinking agents include, but are not limited to, allyl methacrylate and ethylene glycol dimethyacrylate (EGDMA).
• the crosslinking agent is generally used in amounts of from about 0.1 to about 5 weight percent, and generally less than about 2 weight percent, based on the total weight of the monomeric mixture.
• hydrophobic silicon-containing monomer in addition to or in place of the hydrophobic monomers discussed hereinabove. It is particularly advantageous to employ a hydrophobic silicon-containing monomer possessing a sufficient degree of hydrophilicity such that the hydrophobic silicon containing monomer is compatible in the monomeric mixture.
• Suitable hydrophobic silicon-containing monomers include end terminal functionalized trialkoxy silanes such as a trialkoxy silane having a polymerizable ethylenically unsaturated-containing terminal group.
• a representative example of an end terminal functionalized trialkoxy silane is represented by general Formula II: R
• each R independently denotes a lower Q-C I2 alkyl radical such as methyl, ethyl and the like, substituted or unsubstituted C 6 -Ci 2 aryl radical such as a phenyl radical or a group represented by
• each R' independently denotes a lower Ci -C 12 alkyl radical or a substituted or unsubstituted Cf 1 -Cn aryl radical and A is independently a polymerizable ethylenically unsaturated-containing radical.
• a polymerizable ethylenically unsaturated-containing radical include, by way of example, (meth)acrylate-containing radicals, (meth)acrylamide-containing radicals, vinylcarbonate-containing radicals, vinylcarbamate-containing radicals, styrene- containing radicals, vinyl radicals, vinyl ether radicals, maleimide radicals, itaconate radicals, fumarate radicals and the like.
• a polymerizable ethylenically unsaturated-containing radical is represented by general Formula III:
• R 11 is hydrogen or methyl; each R 1 " is independently hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a -
• CO-Y-R 14 radical wherein Y is -O-, -S- or -NH- and R 14 is an alkyl radical having 1 to about 10 carbon atoms;
• R 13 is a divalent alkenyl radical having 1 to about 12 carbon atoms
• B denotes -O- or -NH-
• D denotes -CO-, -OCO- or -COO
• Ar denotes an aromatic radical having 6 to about 30 carbon atoms; w is O to 6; a is O or 1 ; b is O or 1 ; and c is O or 1.
• hydrophobic silicon-containing monomers include those of the Formulae IV-VI:
• the hydrophobic silicon-containing monomer will ordinarily be present in the monomeric mixture in an amount ranging from about 0.5 to about 25 weight percent and preferably from about 1 to about 10 weight percent, based on the total weight of the monomeric mixture.
• an end terminal functionalized surfactant can be included in the monomer mixture.
• a suitable end terminal functionalized surfactant includes, by way of example, one or more end terminal functionalized polyethers.
• Useful polyethers to be end terminal functionalized comprise one or more chains or polymeric components which have one or more (-O-R-) repeats units wherein R is an alkylene or arylene group having 2 to about 6 carbon atoms.
• the polyethers may be derived from block copolymers formed from different ratio components of ethylene oxide (EO) and propylene oxide (PO). Such polyethers and their respective component segments may include different attached hydrophobic and hydrophilic chemical functional group moieties and segments.
• a representative example of a suitable polyether which can be end terminal functionalized is a poloxamer block copolymer.
• poloxamer block copolymers One specific class of poloxamer block copolymers are those available under the trademark Pluronic (BASF Wyandotte Corp., Wyandotte, Mich.). Poloxamers include Pluronics and reverse Pluronics. Pluronics are a series of ABA block copolymers composed of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) blocks as generally represented in Formula VII:
• Reverse Pluronics are a series of BAB block copolymers, respectively composed of poly(propylene oxide)-poly(ethylene oxide)-poly(propylene oxide) blocks as generally represented in Formula VIII:
• the poloxamers in each series have varying ratios of PEO and PPO which ultimately determines the hydrophilic-lipophilic balance (HLB) of the material, i.e., the varying HLB values are based upon the varying values of a and b, a representing the number of hydrophilic polyCethylene oxide) units (PEO) being present in the molecule and b representing the number of hydrophobic poly(propylene oxide) units (PPO) being present in the molecule.
• HLB hydrophilic-lipophilic balance
• Poloxamers and reverse poloxamers have terminal hydroxyl groups that can be terminal functionalized.
• An example of a terminal functionalized poloxamer and as discussed hereinbelow is poloxamer dimethacrylate (e.g., Pluronic ® F127 dimethacrylate) as disclosed in U.S. Patent Application Publication No. 2003/0044468.
• Other examples include glycidyl-terminated copolymers of polyethylene glycol and polypropylene glycol as disclosed in U.S. Patent No. 6,517,933.
• a poloxamine block copolymer Another example of a suitable polyether which can be end terminal functionalized is a poloxamine block copolymer. While the poloxamers and reverse poloxamers are considered to be difunctional molecules (based on the terminal hydroxyl groups), the poloxamines are in a tetrafunctional form, i.e., the molecules are tetrafunctional block copolymers terminating in primary hydroxyl groups and linked by a central diamine.
• Tetronic BASF
• Poloxamines include Tetronic and reverse Tetronics. Poloxamines have the following general structure of Formula IX: HO(C 2 H 4 O) 3 (C 3 H 6 O) 15 (C 3 H 6 O) 13 (C 2 H 4 O) 3 H
• a is independently at least 1 and b is independently at least 1.
• the poloxamer and/or poloxamine is functional ized to provide the desired reactivity at the end terminal of the molecule.
• the functionality can be varied and is determined based upon the intended use of the functionalized PEO- and PPO-containing block copolymers. That is, the PEO- and PPO-containing block copolymers are reacted to provide end terminal functionality that is complementary with the intended device forming monomer mixture.
• block copolymer as used herein shall be understood to mean a poloxamer and/or poloxamine as having two or more blocks in their polymeric backbone(s).
• selection of the functional end group is determined by the functional group of the reactive molecule(s) in the monomer mix. For example, if the reactive molecule contains a carboxylic acid group, glycidyl methacrylate can provide a methacrylate end group. If the reactive molecule contains hydroxy or amino functionality, isocyanato ethyl methacrylate or (meth)acryloyl chloride can provide a methacrylate end group and vinyl chloro formate can provide a vinyl end group.
• glycidyl methacrylate can provide a methacrylate end group.
• isocyanato ethyl methacrylate or (meth)acryloyl chloride can provide a methacrylate end group and vinyl chloro formate can provide a vinyl end group.
• the functional group may comprise a moiety selected from amine, hydrazine, hydrazide, thiol (nucleophilic groups), carboxylic acid, carboxylic ester, including imide ester, orthoester, carbonate, isocyanate, isothiocyanate, aldehyde, ketone, thione, alkenyl, acrylate, methacrylate, acrylamide, sulfone, maleimide, disulfide, iodo, epoxy, sulfonate, thiosulfonate, silane, alkoxysilane, halosilane, and phosphoramidate.
• amine hydrazine, hydrazide, thiol (nucleophilic groups)
• carboxylic acid carboxylic ester, including imide ester, orthoester, carbonate, isocyanate, isothiocyanate, aldehyde, ketone, thione, alkenyl, acrylate
• succinimidyl ester or carbonate imidazolyl ester or carbonate, benzotriazole ester or carbonate, p-nitrophenyl carbonate, vinyl sulfone, chloroethylsulfone, vinylpyridine, pyridyl disulfide, iodoacetamide, glyoxal, dione, mesylate, tosylate, and tresylate.
• activated carboxylic acid derivatives as well as hydrates or protected derivatives of any of the above moieties (e.g.
• Preferred electrophilic groups include succinimidyl carbonate, succinimidyl ester, maleimide, benzotriazole carbonate, glycidyl ether, imidazoyl ester, p-nitrophenyl carbonate, acrylate, tresylate, aldehyde, and orthopyridyl disulfide.
• reaction sequences by which PEO- and PPO- containing block copolymers can be end-functionalized are provided below.
• PEO- and PPO-containing block copolymers are presently preferred.
• An example of such a copolymer that can be used with the method of the invention is Pluronic ® F 127, a block copolymer having the structure [(polyethylene oxide) 99- (polypropylene oxide) 66 -(polyethylene oxide) ⁇ ].
• the terminal hydroxyl groups of the copolymer are functionalized to allow for the reaction of the copolymer with other ophthalmic device forming monomers.
• an end terminal functionalized surfactant is selected from the group consisting of poloxamers having at least one end terminal functionalized, reverse poloxamers having at least one end terminal functionalized, poloxamines having at least one end terminal functionalized, reverse poloxamines having at least one end terminal functionalized and mixtures thereof.
• the end terminal functionalized surfactants will be present in the monomeric mixtures in an amount ranging from about 0.01 to about 20 weight percent, preferably from about 1 to about 10 weight percent, and most preferably from about 3 to about 6 weight percent, based on the total weight of the mixture.
• the monomeric mixture may further contain, as necessary and within limits not to impair the purpose and effect of the present invention, various additives such as an antioxidant, coloring agent, ultraviolet absorber, lubricant internal wetting agents, toughening agents and the like and other constituents as is well known in the art.
• various additives such as an antioxidant, coloring agent, ultraviolet absorber, lubricant internal wetting agents, toughening agents and the like and other constituents as is well known in the art.
• the polymerization products disclosed herein can be obtained by polymerizing the monomer mixture by conventional techniques for polymerization, typically thermal or photochemical polymerization. For thermal polymerization, a temperature from about 40 0 C to about 120 0 C is used. For photochemical polymerization, radiation such as gamma, ultraviolet (UV), visible, or microwave radiation may be used.
• Polymerization is generally performed in a reaction medium, such as, for example, a solution or dispersion using a solvent, e.g., water or an alkanol containing from 1 to 4 carbon atoms such as methanol, ethanol or propan-2-ol. Alternatively, a mixture of any of the above solvents may be used.
• a solvent e.g., water or an alkanol containing from 1 to 4 carbon atoms such as methanol, ethanol or propan-2-ol.
• a mixture of any of the above solvents may be used.
• a polymerization initiator may be included in the mixture to facilitate the polymerization step.
• Representative free radical thermal polymerization initiators are organic peroxides such as, for example, acetal peroxide, lauroyl peroxide, decanoyl peroxide, stearoyl peroxide, benzoyl peroxide, tertiarylbutyl peroxypivalate, peroxydicarbonate, and the like and mixtures thereof.
• UV initiators are those known in the field such as, for example, benzoin methyl ether, benzoin ethyl ether, Darocure 1 173, 1 164, 2273, 1 1 16, 2959, 3331 (EM Industries) and Igracure 651 and 184 (Ciba-Geigy), and the like and mixtures thereof.
• the initiator will be employed in the monomeric mixture at a concentration at about 0.1 to about 5 percent by weight of the total mixture.
• polymerization can be carried out for about 15 minutes to about 72 hours, and under an inert atmosphere of, for example, nitrogen or argon. If desired, the resulting polymerization product can be dried under vacuum, e.g., for about 5 to about 72 hours or left in an aqueous solution prior to use.
• an inert atmosphere for example, nitrogen or argon.
• the resulting polymerization product can be dried under vacuum, e.g., for about 5 to about 72 hours or left in an aqueous solution prior to use.
• hydrophobic substrates include, but are not limited to, polypropylene, polystyrene, silanized glass and the like and combinations thereof.
• the hydrophobic monomer(s) in the monomer mixture will migrate towards the hydrophobic substrate and form an evaporative dehydration barrier layer on the top surface of the ophthalmic device thus obtained.
• the evaporative dehydration barrier layer may not only prevent the water in the high content ophthalmic device of the present invention from evaporating and thereby leaving the device but also prevent the water in the cornea from leaving the cornea to replace the water in the device. This would therefore allow the device to retain its initial water content more effectively and substantially reduce the extraction of water from the corneal surface.
• the ophthalmic devices of the present invention exhibit a dehydration rate of less than or equal to about 0.600 mg/minute. In another embodiment, the ophthalmic devices of the present invention exhibit a dehydration rate of less than or equal to about 0.544 mg/minute. In yet another embodiment, the ophthalmic devices of the present invention exhibit a dehydration rate of less than or equal to about 0.450 mg/minute.
• the evaporative dehydration barrier layer of the ophthalmic devices of the present invention can have a contact angle of about 20 to about 150 and preferably from about 50 to about 90.
• the contact angles of the evaporative dehydration barrier layer of the ophthalmic device can be determined according to the Sessile Drop Method as expanded upon by Zisman et al., J. Colloid ScL, Vol. 1, p. 513 ( 1946). In the method, the ophthalmic device is placed on a flat plate in a goniometer such as a Rane-Hart.
• a drop of liquid of interest e.g., distilled water, buffered saline or any other probe liquid of interest
• the angle can be read from the viewer, after adjusting the baseline.
• contact angles can also be employed.
• Representative examples of such methods for determining a contact angle include an expanded sessile drop technique using multiple liquids of homologous series to generate Zisman plots to obtain the critical surface tension, or theta condition that is determined from a Baier plot of bioadhesion; dynamic contact angles based on the Wilhelmy plate technique; and the captive bubble technique in which the contact angle is of an air bubble at the interface between the solid test surface and a chosen liquid medium.
• the contact angle at an interface is dependent on the solid-liquid-gas interface, and is dependent on the properties of all three.
• a contact angle for a solid test material can greatly change by a change in the choice of the liquid, such as a change from distilled water to borate buffered saline.
• the liquid medium is fixed and the solid test surface has a change in the surface from one layer to the next.
• Such a measure of hydrophilicity is indicated when using a liquid for the contact angle analysis that is hydrophilic, so that a reduced contact angle on the surface is indicative of a decreased hydrophobicity and thus an increased hydrophilicity.
• various analytical techniques such as angle dependent X-ray photoelectron spectroscopy (AD- XPS), or Time of Flight-Secondary Ion Mass Spectroscopy (TOF-SIMS) may be used to probe the surface confirm that the evaporative dehydration barrier layer is present on the surface of the ophthalmic device.
• the ophthalmic device such as a contact lens of the present invention may be subjected to optional machining operations.
• the optional machining steps may include buffing or polishing a lens edge and/or surface.
• such machining processes may be performed before or after the product is released from a mold part, e.g., the lens is dry released from the mold by employing vacuum tweezers to lift the lens from the mold, after which the lens is transferred by means of mechanical tweezers to a second set of vacuum tweezers and placed against a rotating surface to smooth the surface or edges. The lens may then be turned over in order to machine the other side of the lens.
• the lens may then be transferred to individual lens packages containing a buffered saline solution.
• the saline solution may be added to the package either before or after transfer of the lens.
• Appropriate packaging designs and materials are known in the art.
• a plastic package is releasably sealed with a film. Suitable sealing films are known in the art and include foils, polymer films and mixtures thereof.
• the sealed packages containing the lenses are then sterilized to ensure a sterile product. Suitable sterilization means and conditions are known in the art and include, for example, autoclaving.
• steps may be included in the molding and packaging process described above.
• Such other steps can include, for example, coating the formed lens, surface treating the lens during formation (e.g., via mold transfer), inspecting the lens, discarding defective lenses, cleaning the mold halves, reusing the mold halves, and the like and combinations thereof.
• coating the formed lens e.g., via mold transfer
• inspecting the lens discarding defective lenses
• cleaning the mold halves e.g., via mold transfer
• NDP N-vinyl- 2-pyrrolidone
• TBE 4-t-butyl-2-hydroxycyclohexyl methacrylate
• EGDMA ethylene glycol dimethacrylate
• AMA allyl methacrylate
• HEMA 2-hydroxyprop
• the rate of evaporative dehydration for the contact lens was 0.544 mg/min.
• the rate of dehydration was determined from the slope of the initial linear region of the plot of weight (in mg) versus time as measured by a TA Instruments Q50 Thermal Gravimetric Analyzer (TGA). A disk punched from the center of the lens was placed in the TGA and allowed to dry under an N 2 atmosphere while the weight loss was monitored.
• TGA Thermal Gravimetric Analyzer
• a monomer mixture was prepared by mixing the following components, NVP (90 weight percent); TBE (10 weight percent) and EGDMA (0.3 weight percent) and a Vazo 64 initiator (0.5 weight percent). To this mixture was added increasing amounts of O-(methacryloxyethyl)-N-(triethoxysilylpropyl)urethane (MTU) up to 15 weight percent .
• MTU O-(methacryloxyethyl)-N-(triethoxysilylpropyl)urethane
• the monomelic mixture was cast in a polypropylene contact lens mold and thermally cured for about 4 hours.
• the resulting contact lens had an EWC of approximately 80 wt. %.
• the rate of evaporative dehydration for the contact lens was 0.416 mg/minute.
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA 0.3 weight percent
• Vazo 64 initiator 0.5 weight percent.
• the resultant monomeric mixture was cast in a polypropylene contact lens mold and thermally cured for about 4 hours.
• the resulting contact lens had an EWC of approximately 80 wt. %.
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA 0.3 weight percent
• DM dimethacrylate
• Vazo 64 initiator 0.5 weight percent
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA 0.3 weight percent
• Vazo 64 initiator 0.5 weight percent
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA (0.15 weight percent
• HEMA-VC HEMA- vinyl carbamate
• Vazo 64 initiator 0.5 weight percent
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA (0.15 weight percent
• HEMA- VC (0.15 weight percent
• DM Pluronics ® F38 dimethacrylate
• the resultant monomeric mixture was cast in a polypropylene contact lens mold and thermally cured for about 4 hours.
• the resulting contact lens had an EWC of approximately 80 wt. %.
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA 0.15 weight percent
• HEMA- VC (0.15 weight percent
• DM Pluronics ® F38 dimethacrylate
• the resultant monomeric mixture was cast in a polypropylene contact lens mold and thermally cured for about 4 hours.
• the resulting contact lens had an EWC of approximately 80 wt. %.
• NVP 90 weight percent
• TBE 10 weight percent
• EGDMA 0.15 weight percent
• HEMA- VC (0.15 weight percent
• DM Pluronics ® F38 dimethacrylate
• the resultant monomeric mixture was cast in a polypropylene contact lens mold and thermally cured for about 4 hours.
• the resulting contact lens had an EWC of approximately 80 wt. %.

Landscapes

• Physics & Mathematics (AREA)
• Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Optics & Photonics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Ophthalmology & Optometry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Eyeglasses (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40602631

Family Applications (1)

Country Status (6)

Cited By (2)

Families Citing this family (72)

Citations (4)

Family Cites Families (22)

• 2009
  • 2009-01-08 US US12/350,262 patent/US8138290B2/en active Active
  • 2009-01-21 EP EP09703382.3A patent/EP2238482B1/en active Active
  • 2009-01-21 JP JP2010544391A patent/JP5290327B2/ja active Active
  • 2009-01-21 ES ES09703382T patent/ES2416730T3/es active Active
  • 2009-01-21 WO PCT/US2009/031504 patent/WO2009094356A1/en not_active Ceased
  • 2009-01-21 CN CN2009801029080A patent/CN101981470A/zh active Pending
• 2012
  • 2012-02-10 US US13/370,364 patent/US8389597B2/en active Active
• 2013
  • 2013-06-03 JP JP2013116868A patent/JP2013190823A/ja active Pending

Patent Citations (5)

Also Published As

Similar Documents

Legal Events